start moving towards that. This could be a topic, one of the topics, for the Biopharmaceutics Subcommittee, to come up with a general decision tree criteria of how we approach endogenous substances. Today we do that on the basis of each product, each drug, and I think we're very confident that our system works. But I think it would be helpful to move from going for each drug-specific issue to create a framework of a decision tree. So the discussion on that is focused on where do we go from here to a decision tree criteria.
We'll end this day with a look at some of the activities, research activities in our immediate office. There are two points that I would like to make with that.
One is as we move towards a quality system approach to thinking, there has to be a mechanism for evaluating how good we are. We, for several years, had a committee called Therapeutic Inequivalence Action Coordinating Committee. We talked about it briefly yesterday. What Helen has asked me to do is to take responsibility for that committee and we have taken a step back to evaluate how best do we assess and evaluate and manage that process? What is that process? It is a